NASDAQ:ASND - Ascendis Pharma A/S Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $180.25
  • Forecasted Upside: 9.30 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 12 Buy Ratings
  • 0 Strong Buy Ratings
$164.92
▼ -3.33 (-1.98%)
1 month | 3 months | 12 months
Get New Ascendis Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASND

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$180.25
▲ +9.30% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $180.25, with a high forecast of $208.00 and a low forecast of $145.00. The average price target represents a 9.30% upside from the last price of $164.92.
Buy
The current consensus among 12 polled investment analysts is to buy stock in Ascendis Pharma A/S. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/12/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/10/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2019
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/6/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/4/2020
  • 0 strong buy ratings
  • 11 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/3/2020
  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020

Latest Recommendations

  • 0 strong buy ratings
  • 12 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/13/2020Morgan StanleyBoost Price TargetOverweight$194.00 ➝ $199.00Low
i
11/12/2020Wells Fargo & CompanyBoost Price TargetOverweight$176.00 ➝ $190.00High
i
11/12/2020Credit Suisse GroupBoost Price TargetOutperform$158.00 ➝ $178.00High
i
11/12/2020SVB LeerinkBoost Price TargetOutperform$173.00 ➝ $191.00High
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$179.00 ➝ $194.00Low
i
9/30/2020WedbushBoost Price TargetOutperform$187.00 ➝ $206.00Medium
i
Rating by Liana Moussatos at Wedbush
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweightMedium
i
8/31/2020Morgan StanleyBoost Price TargetOverweight$177.00 ➝ $179.00High
i
8/28/2020Credit Suisse GroupBoost Price TargetOutperform$154.00 ➝ $158.00Medium
i
7/15/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $177.00Low
i
6/26/2020WedbushInitiated CoverageBuy$188.00Low
i
5/21/2020Morgan StanleyBoost Price TargetOverweight$180.00 ➝ $181.00Low
i
5/20/2020CSFBBoost Price TargetOutperform$149.00 ➝ $154.00Medium
i
5/20/2020SVB LeerinkBoost Price TargetOutperform$170.00 ➝ $173.00Low
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/20/2020Credit Suisse GroupBoost Price TargetOutperform$149.00 ➝ $154.00High
i
5/20/2020OppenheimerLower Price TargetOutperform$219.00 ➝ $208.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
4/20/2020SVB LeerinkBoost Price TargetPositive ➝ Outperform$152.00 ➝ $170.00High
i
Rating by Joseph Schwartz at SVB Leerink LLC
4/20/2020JPMorgan Chase & Co.Boost Price TargetOverweight$145.00 ➝ $150.00High
i
4/20/2020OppenheimerBoost Price TargetOutperform$199.00 ➝ $219.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
4/20/2020Canaccord GenuityBoost Price TargetBuy$166.00 ➝ $170.00High
i
4/20/2020Credit Suisse GroupBoost Price TargetIn-Line ➝ Outperform$139.00 ➝ $149.00High
i
4/20/2020Cantor FitzgeraldBoost Price TargetOverweight$185.00 ➝ $201.00High
i
4/20/2020Stifel NicolausBoost Price TargetBuy$146.00 ➝ $171.00High
i
4/2/2020Morgan StanleyLower Price TargetOverweight$181.00 ➝ $180.00Medium
i
3/31/2020Canaccord GenuityBoost Price TargetBuy$144.00 ➝ $166.00High
i
3/27/2020Bank of AmericaReiterated RatingBuy$145.00Medium
i
3/19/2020OppenheimerInitiated CoverageOutperform$199.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
2/26/2020Morgan StanleyBoost Price TargetOverweight$148.00 ➝ $181.00Low
i
1/17/2020Morgan StanleyBoost Price TargetOverweight$140.00 ➝ $148.00Medium
i
12/17/2019Morgan StanleyBoost Price TargetOverweight$134.00 ➝ $140.00High
i
12/3/2019SVB LeerinkReiterated RatingPositive ➝ Outperform$140.00 ➝ $152.00Medium
i
11/19/2019WedbushReiterated RatingBuy$186.00High
i
Rating by Liana Moussatos at Wedbush
10/22/2019WedbushLower Price TargetPositive ➝ Outperform$191.00 ➝ $186.00High
i
Rating by Liana Moussatos at Wedbush
10/11/2019Morgan StanleyInitiated CoverageOverweight$128.00High
i
9/24/2019WedbushSet Price TargetBuy$191.00Low
i
Rating by Liana Moussatos at Wedbush
8/29/2019JPMorgan Chase & Co.Boost Price TargetOverweight$143.00 ➝ $152.00High
i
6/28/2019WedbushReiterated RatingBuy$223.00Low
i
Rating by Liana Moussatos at Wedbush
6/10/2019WedbushSet Price TargetBuy$223.00Low
i
Rating by Liana Moussatos at Wedbush
6/3/2019WedbushBoost Price TargetOutperform$219.00 ➝ $223.00High
i
Rating by Liana Moussatos at Wedbush
5/31/2019Canaccord GenuityBoost Price TargetBuy$133.00 ➝ $144.00High
i
5/20/2019WedbushSet Price TargetBuy$219.00Medium
i
Rating by Liana Moussatos at Wedbush
4/8/2019WedbushReiterated RatingBuy$219.00High
i
Rating by Liana Moussatos at Wedbush
4/5/2019Canaccord GenuityBoost Price TargetBuy ➝ Buy$132.00 ➝ $133.00Low
i
3/29/2019Credit Suisse GroupLower Price TargetOutperform ➝ Outperform$151.00 ➝ $139.00Low
i
3/26/2019WedbushReiterated RatingBuy$217.00Medium
i
Rating by Liana Moussatos at Wedbush
3/25/2019Evercore ISIInitiated CoverageOutperform ➝ OutperformHigh
i
3/18/2019Cantor FitzgeraldReiterated RatingBuy$185.00Low
i
Rating by A. Young at Cantor Fitzgerald
3/7/2019WedbushSet Price TargetOutperform$81.00 ➝ $217.00Medium
i
Rating by Liana Moussatos at Wedbush
3/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight$85.00 ➝ $145.00Medium
i
3/4/2019Cantor FitzgeraldReiterated RatingOverweight$102.00 ➝ $185.00High
i
Rating by A. Young at Cantor Fitzgerald
1/25/2019WedbushSet Price TargetBuy$81.00High
i
Rating by Liana Moussatos at Wedbush
1/24/2019SVB LeerinkUpgradeMarket Perform ➝ Outperform$73.00 ➝ $90.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
1/23/2019Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$102.00Low
i
Rating by A. Young at Cantor Fitzgerald
11/29/2018Credit Suisse GroupBoost Price TargetOutperform$80.00 ➝ $86.00High
i
11/9/2018Credit Suisse GroupInitiated CoverageOutperform$80.00Low
i
8/30/2018WedbushSet Price TargetBuy$79.00Low
i
Rating by Liana Moussatos at Wedbush
8/30/2018JPMorgan Chase & Co.Boost Price TargetOverweight$79.00 ➝ $81.00Low
i
8/30/2018Wells Fargo & CompanyBoost Price TargetOutperform$83.00 ➝ $88.00High
i
8/30/2018Stifel NicolausLower Price TargetBuy ➝ Buy$85.00 ➝ $81.00High
i
8/7/2018Canaccord GenuityInitiated CoverageBuy$81.00Low
i
6/26/2018Stifel NicolausInitiated CoverageBuy$85.00Medium
i
5/31/2018SVB LeerinkReiterated RatingMarket Perform$64.00 ➝ $70.00Medium
i
Rating by J. Schwartz at SVB Leerink LLC
5/15/2018WedbushReiterated RatingOutperform$76.00Low
i
4/20/2018WedbushReiterated RatingTop Pick$76.00High
i
4/4/2018WedbushLower Price TargetOutperform$76.00 ➝ $67.00Low
i
4/2/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$37.00 ➝ $64.00High
i
Rating by J. Schwartz at SVB Leerink LLC
3/21/2018JPMorgan Chase & Co.Boost Price TargetOverweight$75.00High
i
Rating by Jessica Fye at JPMorgan Chase & Co.
3/20/2018Credit Suisse GroupBoost Price TargetOutperform ➝ Outperform$50.00 ➝ $78.00High
i
2/26/2018WedbushReiterated RatingOutperform$67.00Low
i
2/25/2018Credit Suisse GroupReiterated RatingBuy$50.00Low
i
2/6/2018WedbushReiterated RatingOutperform$62.00Low
i
1/25/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$45.00 ➝ $60.00High
i
1/19/2018HC WainwrightReiterated RatingBuyMedium
i
1/17/2018JPMorgan Chase & Co.Reiterated RatingBuy$60.00Medium
i
Rating by Jessica Fye at JPMorgan Chase & Co.
1/3/2018JPMorgan Chase & Co.Set Price TargetBuy$50.00Low
i
Rating by Jessica Fye at JPMorgan Chase & Co.
12/13/2017HC WainwrightReiterated RatingBuyLow
i
11/17/2017Bank of AmericaLower Price TargetBuy$46.00 ➝ $43.00N/A
i
9/28/2017Bank of AmericaBoost Price Target$36.00 ➝ $46.00Low
i
9/25/2017Bank of AmericaReiterated RatingBuy$34.00 ➝ $36.00High
i
9/22/2017Wells Fargo & CompanyReiterated RatingBuy$51.00High
i
9/22/2017Credit Suisse GroupReiterated RatingOutperform$30.00 ➝ $50.00High
i
Rating by Alethia Young at Credit Suisse Group AG
9/22/2017WedbushReiterated RatingOutperform$65.00 ➝ $10.71High
i
9/1/2017SVB LeerinkReiterated RatingHold$28.00High
i
Rating by J. Schwartz at SVB Leerink LLC
7/18/2017Credit Suisse GroupSet Price TargetBuy$28.00High
i
Rating by Alethia Young at Credit Suisse Group AG
5/25/2017SVB LeerinkLower Price TargetMarket Perform$30.00 ➝ $26.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
5/24/2017WedbushReiterated RatingOutperform$36.00 ➝ $34.00Low
i
5/11/2017JPMorgan Chase & Co.Initiated CoverageOverweight$36.00Low
i
4/3/2017WedbushReiterated RatingOutperform$34.00Low
i
3/24/2017WedbushBoost Price TargetOutperform$31.00 ➝ $34.00High
i
3/9/2017SVB LeerinkDowngradeOutperform ➝ Market Perform$24.00 ➝ $30.00Low
i
Rating by J. Schwartz at SVB Leerink LLC
2/23/2017WedbushReiterated RatingOutperform$31.00N/A
i
2/9/2017Credit Suisse GroupInitiated CoverageOutperform$28.00N/A
i
2/8/2017WedbushReiterated RatingOutperform$31.00N/A
i
12/16/2016WedbushReiterated RatingOutperform$31.00N/A
i
12/1/2016SVB LeerinkReiterated RatingBuy$24.00N/A
i
12/1/2016WedbushReiterated RatingOutperform$31.00N/A
i
10/20/2016WedbushReiterated RatingOutperform$31.00N/A
i
9/26/2016WedbushInitiated CoverageOutperform$34.00N/A
i
Rating by L. Moussatos at Wedbush
9/2/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Joseph Schwartz at SVB Leerink LLC
5/26/2016SVB LeerinkReiterated RatingOutperform$24.00N/A
i
(Data available from 12/3/2015 forward)
Ascendis Pharma A/S logo
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Read More

Today's Range

Now: $164.92
$164.92
$169.00

50 Day Range

MA: $162.23
$151.20
$174.79

52 Week Range

Now: $164.92
$92.00
$178.26

Volume

117,554 shs

Average Volume

200,620 shs

Market Capitalization

$8.81 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79